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 Arthritis is a very common chronic debilitating disease in people and dogs alike. 
It does not discriminate based on species, and one in five dogs suffer from osteoarthritis. 
The purpose of this study was to evaluate the safety and anti-arthritic efficacy of a 
nutraceutical, Flex Choice, in moderately arthritic canines. Five moderately arthritic 
canines that weighed between 40-65 pounds were selected for this study. Moderate 
arthritis was considered a ranking of 4-6 on a scale of 1-10 with 1 being no/minimal pain 
and 10 being severe and constant pain. All five canines were orally administered one Flex 
Choice soft chew twice a day for 150 days. There was no control group due to limited 
population. Day 0 baseline results were used as the control. On days 0, 30, 60, 90, 120, 
and 150 of the study, the canines were evaluated for overall joint pain, pain during limb 
manipulation, and pain after physical exertion. Radiographs were also performed on days 
0 and 150 to observe if osteophyte formation may have been reduced. Serum chemistry 
analysis was performed each month as well to see if Flex Choice had any adverse effects 
on kidney, liver, or heart function. Body weight, heart rate, respiration rate, and 
temperature were also evaluated throughout the entire study. 
 Treated canines had a significant reduction in overall pain levels, pain during limb 
manipulation, and pain after physical exertion at some point during the study with P < 
0.05. Serum chemistry indicated no significant side effects to vital organs throughout the 
entire study. Heart rate, body weight, respiration rate, and temperature were not 
significantly affected by the administration of Flex Choice chews. This study proves that 
Flex Choice is a safe and effective way to reduce pain and inflammation associated with 
canine osteoarthritis and may provide alternatives to NSAIDs.  
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Chapter I: Introduction 
 
 Arthritis is a chronic, painful disease that affects many humans and targets joints 
such as the wrist, hip and knee. Just like humans, dogs and other animals can be affected 
by this disease. There is no cure for arthritis, but veterinarians can perform surgeries and 
prescribe pharmaceuticals or nutraceuticals to help improve the joint’s flexibility and to 
help reduce pain (Arthritis in Dogs, n.d.). 
Osteoarthritis is the most common type or arthritis in dogs. Osteoarthritis, which 
is also commonly known as degenerative joint disease, is a debilitating disease that 
affects one in five dogs (Arthritis in Dogs, n.d.). Osteoarthritis can be either one of two 
types of arthritis: primary or secondary. Primary osteoarthritis is a condition in which 
cartilage in the joint degenerates as the dog ages. Secondary osteoarthritis occurs 
secondary to joint disease, instability of the joint, or abnormal pressure on cartilage in the 
joint (Texas A&M Veterinary Medicine & Biomedical Sciences, 2016).  
Although osteoarthritis is not breed, age, or sex specific, there may be 
predisposing factors. Senior dogs tend to be more prone to developing arthritis as they 
age (Innes, 1995). Dogs who are overweight are more prone to arthritis due to increased 
impact on joints. Other factors, including genetics and injuries, may make some dogs 
more prone to arthritis than others (American College of Veterinary Surgeons, n.d.). 
 Symptoms of arthritis in dogs include activity impairment and pain. Dogs who 
are suffering from osteoarthritis may not exercise as much as they once did, or they may 
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have a harder time getting up or lying down. They may also experience depression and 
sleep more than they used to. In order to properly diagnose osteoarthritis, a veterinarian 
will perform a physical exam to assess joint mobility and pain and radiographs are used 
to determine the extent of damage to joints caused by arthritis (American College of 
Veterinary Surgeons, n.d.).  
Since there is no cure for this disease, veterinarians do their best to make the dogs 
more comfortable. Weight management and exercise are common practices in managing 
arthritis in dogs. Exercise helps loosen stiff joints and helps dogs shed the extra pounds 
that are adding more stress to joints. Non-steroidal anti-inflammatories (NSAIDs) are a 
commonly prescribed medication to arthritic dogs. A disadvantage to NSAIDs is they 
eliminate pain associated with the joint damage caused by arthritis, but do not reverse 
damage and can produce side effects if given long term. Nutraceuticals are becoming 
more popular because they not only help with pain associated with arthritis, but they 
consist of ingredients found in cartilage, therefore promoting healthy joints and 
preventing further damage (Arthritis in Dogs, n.d.). 
Statement of the Problem 
 
 According to literature, one in five dogs suffer from osteoarthritis and that use of 
certain pain management drugs, such as NSAIDs, may do more harm than good (Arthritis 




 The purpose of this study was to determine anti-arthritic efficacy and safety of 
Flex Choice in moderately osteoarthritic dogs. A comparison of pain assessment, 
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radiography, physical examination, and blood tests was used by the researcher to test 
efficacy and safety of the nutraceutical. This multi-method study was composed of three 
major components. Assessment of pain was the first component. This was measured 
using a standardized scale and a physical exam was performed to help determine level of 
pain. Additionally, blood tests including chemistry panels, complete blood counts (CBC), 
and erythrocyte sedimentation rate (ESR) were used to assess the effects Flex Choice had 




H0: (Null) There will not be a clinically significant difference in canines treated with 
Flex Choice. 
H1: (Research hypothesis) Canines treated with Flex Choice will have a clinically 
significant reduction in pain. 
Objective 
 
The research study was guided by the following objectives: 
1. Determine anti-arthritic efficacy of the nutraceutical, Flex Choice, in moderately 
arthritic canines through subjective data, such as overall pain, pain after limb 
manipulation and pain after physical exertion. 
2. Determine safety and tolerability of the nutraceutical, Flex Choice, in moderately 
arthritic canines through evaluation of objective data, such as heart rate, respiration 




Definition of Terms 
 
1. Osteoarthritis- the most common form of arthritis. It is caused by the wear and 
tear of a joint and gradually worsens over time (Center for Disease Control and 
Prevention, 2018). 
2. Joint- Any point in which two or more bones are in contact (Pasquini et al., 2007). 
3. Moderate Arthritis- the level of arthritis in which overall pain is described as a 4-6 
on a scale of 0-10. Cartilage is compressed/damaged, and the bone becomes 
thickened. Exercise is painful for moderately arthritic dogs (Gupta et al., 2011). 
4. Nutraceutical- a constituent of food that is used for human and animal health 
benefits for treating and preventing disease 
5. Flex Choice- a nutraceutical that is being tested in this study. It is composed of 
krill oil, hyaluronic acid, astaxanthin, Boswellia serrata extract, green lipped 
mussel, and iron transport tocopheryl polyethylene glycol succinate (ITPGS). 
6. NSAID (non-steroidal anti-inflammatory drug)- a class of drug that is commonly 
given to arthritic animals to reduce inflammation and pain in joints (Innes, 1995). 
7. Pain- an unpleasant sensation that is conveyed to the brain through sensory 
neurons. The physical discomfort may lead to evasive action and cause injury 
(Gupta et al., 2011). 
8. Cartilage- a fibrous connective tissue that is found at the end of bones in the joints 
that reduces friction and absorbs shock (Pasquini et al., 2007). 
Limitations 
 
This research was restricted by the following limitations: 
1. The study was limited to dogs between 35 and 65 pounds. 
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2. The study was limited to 5 dogs that were considered to be moderately arthritic 
(overall pain of 4-6 on a scale of 0-10). 
3. The study was limited to the use of Flex Choice only. 
4. The study did not evaluate the effects of Flex Choice on dogs of different ages, sexes, 
or breeds. 
5. The study did not attempt to prove that Flex Choice cures arthritis. 
6. The study was limited to 150 days. 
Assumptions 
 
The following assumptions concerning this study were made: 
1. The dogs’ owners would follow directions and give Flex Choice as instructed. 
2. All dogs were not given any pain medication or treatments for arthritis for two weeks 
prior to the start of the study. 
3. All dogs were free of any serious health conditions such as hepatic, renal, or heart 
disease or failure. 
4. All owners would be honest in their assessment and accurately record the dogs’ daily 
pain level. 
5. Differences of age, breed, sex, diet, and lifestyle would have no effect on the efficacy 
of Flex Choice. 
Statement of Significance 
 
 A study to determine the efficacy and safety of new nutraceuticals such as Flex 
Choice, is important for a couple of reasons. First, if a nutraceutical is proven effective, 
then many dogs may receive relief from this debilitating disease of osteoarthritis. Second, 
if a nutraceutical is proven safe, there will be more, safer alternatives to invasive or 
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noninvasive treatments for osteoarthritis. Flex Choice is not intended to cure arthritis, but 
if proven effective, it will give relief to dogs who suffer from this disease and give 
owners a peace of mind that they are helping their dogs stay comfortable.  
Chapter Summary 
 
 Arthritis does not discriminate, but through an understanding of canine 
osteoarthritis and treatments available, it is confirmed that more alternative measures are 
needed. In this particular study, it is predicted that Flex Choice will reduce pain and 
discomfort associated with canine arthritis. There are limitations on weight, duration, 
sample size and assumptions relying on owner compliance are present, but the researcher 









 The purpose of this chapter is to establish the background of osteoarthritis in 
canines and the need for more management options. Literature and research available for 
osteoarthritis in dogs is vast and many researchers are looking for new ways to treat and 
manage the disease and pain in affected canines. Topics covered in this literature review 
were osteoarthritis in canines, joint function and anatomy, and treatment options. 
Osteoarthritis in Canines 
 
 Osteoarthritis is a degenerative joint disease that affects dogs and humans, along 
with all mammals. Osteoarthritis is highly prevalent in adult dogs with more than 20% 
affected. There is no known predisposing factor to osteoarthritis, however, genetics, age, 
breed, and systemic changes such as hormones and disease have been shown to cause 
increased susceptibility. This disease is a very painful, inflammatory degenerative joint 
disease that affects synovial joints including the knee, elbow, hock and stifle. Although 
this disease is slow to progress, it will eventually lead to loss of mobility (Comblain, et 
al, 2015).  
 Although osteoarthritis may be defined in many ways, the American Academy of 
Orthopedic Surgeons defines osteoarthritis as: 
“Osteoarthritic diseases are the result of mechanical and biologic 
events that destabilize normal coupling of degradation and 
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synthesis of articular cartilage chondrocytes, extracellular matrix 
and subchondral bone.” (Budsberg & Bartges, 2006) 
Some initiating factors of osteoarthritis include aberrant repair, degeneration of articular 
cartilage, formation of new bone at the articular margins, sclerosis of subchondral bone 
and low-grade synovial inflammations (Innes, 1995). These initiating factors, along with 
the American Academy of Orthopedic Surgeons’ definition, explain that osteoarthritis is 
caused by the breakdown of cartilage and formation of new bone in its place. This causes 
bone on bone action in joints and leads to pain.  
 Currently, there are three types of osteoarthritis: primary, secondary, and erosive 
osteoarthritis (Innes, 1995). Primary osteoarthritis, also known as idiopathic, has 
unidentified initiating factors. This type also symmetrically affects joints and can affect 
the knees, elbows, hocks, stifles, or any combination as long as joints on both sides (left 
and right limb) are affected. Primary osteoarthritis is not very common in dogs but has 
been documented in young adult dogs of the Chow Chow, Dalmatian, Samoyed, 
Labrador Retriever, and Spaniel breeds. Secondary osteoarthritis is the most common 
type and usually has an identifiable cause (Innes, 1995). Some causes of secondary 
osteoarthritis include trauma, development issues, inflammatory joint disease, or 
metabolic disease. Erosive, or atrophic, osteoarthritis is the third type of osteoarthritis. 
This type is not well documented in dogs, but it may occasionally be detected by erosive 
changes upon radiography (Innes, 1995). 
 Diagnosing osteoarthritis can be difficult since many owners do not seek 
veterinary care until major joint degradation has already occurred or it is brought up in 
conversation at annual vet visits. A history of the patient and examination of the clinical 
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signs is necessary to diagnose osteoarthritis. Signs of osteoarthritis include chronic 
lameness, stiffness, decreased range of motion, and a thickened joint upon palpation, as 
well as the presence of crepitation (Merck, 2016). Joint thickening is caused by capsular 
fibrosis and osteophyte production. Other than evaluation of clinical signs, radiographs 
may be taken to visualize joints and see the extent of osteoarthritis. Arthrocentesis may 
also be performed to evaluate synovial fluid color and viscosity (Innes, 1995).  
Since osteoarthritis is caused by pathological changes in articular cartilage, there 
is no known cure. Pain management measures are the only option in affected animals 
(Innes et al., 2010). There are several forms of pain management that range from invasive 
to non-invasive. 
Joint Function and Anatomy 
 
 Joints are an important part of an animal’s body. Joints work together with bones, 
tendons, and ligaments to allow an animal to move. Synovial joints are the joints most 
commonly affected by osteoarthritis. They are diarthrodial, movable joints that are 
characterized by mobility, joint cavity, articular cartilage, synovial membrane, and a 
fibrous capsule (Pasquini et al., 2007). 
 Joint capsules are a two layered structure that surround joints and are composed 
of an outer fibrous layer and an inner synovial membrane. Fibrous layers attach to 
periosteum on or near margins of the articular cartilage and synovial membranes are 
highly vascular, nerve rich membranes that produce synovial fluid for joints. Synovial 
fluid has the consistency of a raw egg white and lubricates joints. It helps supply nutrients 
to joints and removes waste products. Articular cartilage covers ends of bones and helps 
to reduce friction and concussion. Ligaments are bands of fibrous connective tissue that 
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connect bone to bone. They help keep everything together but still allow for movement 
(Pasquini et al., 2007). Tendons are connective tissue that connect muscle to bone.  
 Synovial joints are called freely movable joints because they can move in 
different ways depending on what classification they are. Simple joints have two articular 
surfaces enclosed in a joint capsule while a compound joint has more than two. There are 
also plane joints that glide, ball-and-socket joints that have a head fitting into a pit, a 
hinge joint that can either increase or decrease the angles between bones, pivot joints that 
allow rotation, and ellipsoidal joints that are convex/concave (Pasquini et al., 2007). 
These are all types of synovial joints that allow the body to move and can be affected by 
osteoarthritis.  
Treatment Options for Osteoarthritis 
 
 Canine osteoarthritis is a very painful disease that requires treatment to keep 
animals comfortable. Without some form of pain management, quality of life will be 
diminished. Fortunately, there are many ways to manage the pain associated with 
osteoarthritis, although precautions must be taken as some are not without adverse side 
effects. Some options for treatment include physical therapy, weight management, 
surgery, medications, and nutraceuticals.  
Physical Therapy and Weight Management 
 
 Since osteoarthritis is a joint disease, mobility may be decreased as the disease 
progresses. It is important to keep dogs with osteoarthritis physically active to keep joints 
moving and at an adequate weight to prevent unnecessary force on joints. It is also 
important to monitor these dogs regularly to ensure they are maintaining movement and 
not gaining weight. (McKee, 2013). Use of a body condition score to monitor weight is 
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strongly advised when this method of arthritis management is selected. This method may 
also be used in conjunction with medication or a nutraceutical.  
Obesity is described as accumulation of excess body fat and increased body 
weight causes excess pressure on joints and cartilage, causing more pain and degradation. 
Adipose tissue, or fat, is considered metabolically active and proinflammatory which 
leads to more inflammation in joints (Budsberg & Bartges, 2006). It is important to keep 
the animal active. Short walks with adequate rest in between are all that is needed.  
Surgery 
 
 Surgery is usually the last resort for dogs with osteoarthritis unless it is secondary 
to an underlying cause. There are only three instances when surgery would be warranted: 
a) to treat underlying causes, b) as an attempt to treat osteoarthritis, or c) to remove or 
replace an osteoarthritic joint (Innes, 1995). There are surgeries that may be performed 
on any joint that can be affected by osteoarthritis. Common surgeries are a cheilectomy 
(removal of osteophytes), articular forage (drilling across metaphyseal scars), excision 
arthroplasty, joint replacement, and arthrodesis (fusion of joints) (Innes, 1995; Mckee, 
2013). 
Medications and Nutraceuticals 
 
 There are a few medications available that can be used for managing pain caused 
by osteoarthritis. There are two classes of drugs that are commonly administered: non-
steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Nutraceuticals are also 
another option rising in popularity. 
Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of drug that are 
considered a mainstay in pain management as they are an analgesic as well as an anti-
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inflammatory. These drugs relieve clinical signs associated with osteoarthritis without a 
myriad of potential metabolic and immunosuppressive adverse effects that are commonly 
associated with corticosteroids (Merck, 2016). NSAIDs act primarily to reduce 
biosynthesis of prostaglandins by inhibiting cyclooxygenase (COX). There are two 
different isoforms of COX that have been discovered (COX-1 and COX-2) and this 
discovery has led to a greater understanding of the mode of action and adverse effects of 
NSAIDs. COX-1 is found in most body tissues and is responsible for mediating a variety 
of normal physiological effects. This includes hemostasis, GI mucosal protection and 
protection of the kidney from hypotensive insult. COX-2 is activated in damaged and 
inflamed tissues and also catalyzes the formation of prostaglandin, which is associated 
with inflammatory response. One downside to use of NSAIDs is that they cannot 
differentiate between the two isoforms of COX, inhibiting positive COX-1 enzymes. This 
contributes to common side effects often seen with use of NSAIDs (Merck, 2016). 
Commonly used NSAIDs include Carprofen, Metacam, Previcox, and others. All 
NSAIDs have the potential to induce adverse effects, including vomiting, gastritis and 
ulceration. GI blood loss may occur and result in iron-deficient anemia. Nephropathies 
and hepatopathies have also been recognized with long term used of NSAIDs (Merck, 
2016). NSAIDs may be used short or long term. However, use must be monitored with 
regular blood work to ensure that organ function is not compromised.  
Corticosteroids are another class of drug used to manage pain associated with 
osteoarthritis. Glucocorticoids are the most common corticosteroids used. 
Glucocorticoids suppress inflammatory responses by interacting with specific 
intracellular receptor proteins in target tissues. Results of the end process include blocked 
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synthesis of prostaglandins, inhibited production of COX enzymes, cytokines, and 
enzymes such as collagenases and aggrecanases. Adverse effects of corticosteroid use 
include polyuria, polydipsia, suppressed immune system, hepatopathy, and reduced 
collagen synthesis (Merck, 2016). Corticosteroids were once commonly used to treat 
osteoarthritis, but NSAIDs have now become a popular treatment. 
 Nutraceuticals are natural supplements that have been shown to reduce 
osteoarthritis effects in dogs. They can be used individually or in combination to form a 
supplement in which effects of each compound are combined to reach a desired effect. 
Nutraceuticals are becoming a popular alternative to other medications such as NSAIDs, 
as they have little to no side effects and are able to lessen pain and discomfort that is 
associated with canine arthritis. There are many different nutraceuticals on the market 
and more are being added regularly due to the increase in popularity. One of the more 
recently introduced nutraceuticals is Flex Choice.  
Flex Choice 
 Flex Choice is categorized as a nutraceutical and was chosen for this study based 
on its analgesic and anti-inflammatory properties. Flex Choice is a joint supplement that 
is composed of krill oil, hyaluronic acid, astaxanthin, Boswellia serrata extract, green 
lipped mussel, and iron transport tocopheryl polyethylene glycol succinate (ITPGS). 
 Krill oil is a source of Omega-3 fatty acids and has been found as a source of 
phospholipids and antioxidants. Omega-3 fatty acids are polyunsaturated fatty acids 
(PUFAs) and are beneficial for treatment of canine osteoarthritis. Fish oils, including krill 
oil, are excellent sources of two out of three types of omega-3 fatty acids involved in 
mammalian systems: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). 
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Omega-3 fatty acids act by reducing IL-1β, PGE2, ADAMTS-4, COX-2, IL-1α, iNOS, 
TNF-α, MMP-3, MMP-13, and aggrecanase and collagenase activities, as well as by 
increasing collagen synthesis. EPA is the most effective type of omega-3, followed by 
DHA. PUFAs have a way to protect activation of autophagy in chondrocytes by 
modulating mammalian targets of rapamycin (mTOR) signaling, therefore making them 
an effective way of treating osteoarthritis (Gupta et al, 2019). 
 Hyaluronic acid (HA) is an anionic, nonsulfated glycosaminoglycan (GAG) that 
is produced by chondrocytes and synovial fibroblasts. HA is an important compound in 
articular cartilage as it coats each chondrocyte. HA size decreases with age but increases 
in volume. It has been shown that treatment with HA of higher molecular weight is more 
effective. There are two common methods of administering HA: intra-articularly (IA) and 
orally. IA treatment with HA has been used for decades as a therapy for osteoarthritis in 
horses and canines. In this method, HA is injected directly into affected joints. Oral 
administration of high molecular weight HA has been proven to also reach joints, making 
it a justified route of supplementation. There is a third method of administration, 
intravenous, but it has not gained popularity and has only been tested in horses. HA is 
effective at treating osteoarthritis as it may have a role in regulating synthesis of 
proteoglycans during maturation of articular cartilage. It may also play a role in repair 
processes of articular joints. HA works by mitigating activities of pro-inflammatory 
mediators and pain-producing neuropeptides that are released by activated synovial cells. 
HA can also reduce nerve impulses and sensitivity that is associated with pain from 
osteoarthritis. In osteoarthritis, treatment is usually the only option for management, but 
studies have shown that HA prevents degradation of cartilage and may even promote 
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regeneration. There are some adverse side effects associated with HA, but they are 
mainly associated with IA administration route. These side effects include muscle pain, 
cramping, pain in the injected joint, and swelling of arms and legs. This may make 
movement difficult. Overall, HA is a slow acting anti-osteoarthritic agent that can be 
used as an anti-inflammatory disease-modifying agent in osteoarthritis (Gupta, 2016; 
Gupta et al, 2019a, b). 
 Astaxanthin (AXT) is a xanthophyll carotenoid that is present in many microalgae 
and yeasts. AXT possesses strong antioxidant activity because it neutralizes singlets of 
oxygen, scavenges free radicals, inhibits lipid peroxidation, enhances immune system 
function, and regulates gene expression. AXT also contributes to glucose metabolism and 
decreases lipid accumulation in the liver (Gupta, 2016). Although AXT does not have 
any direct links to managing or treating osteoarthritis, it does have many health benefits 
that contribute to its use as a supplement. AXT can be used for neuroprotection by 
reducing oxidative stress, suppressing expression of inflammatory cytokines, protecting 
gastric mucosal linings by stimulating the anti-oxidative mechanism, and by boosting the 
immune system. There have not been any side effects reported from use of AXT as a 
dietary supplement (Gupta, 2016).  
 Boswellia serrata, commonly called Indian Frankincense, is a plant that is native 
to India and its extract has many health benefits. Boswellic acids (alpha- and beta-
boswellic acids) are the main component of B. serrata extract. These are organic acids 
that consist of a pentacyclic triterpene, a carboxyl group, and at least one other functional 
group. Acetyl-keto-beta-boswellic acid (AKBA) contributes most to health benefits and 
is present in concentrations of 2-3% of the extract. Boswellic acids have been effective in 
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treatments for ulcerative colitis, chemically induced hepatic damage, bronchial asthma, 
and other diseases such as osteoarthritis. Acetyl-boswellic acids have exhibited anti-
inflammatory properties by inhibiting leukotriene synthesis. In some studies, 30% AKBA 
provided improvement in joint mobility and comfort in as little as one week (Gupta, 
2016). 
 Green lipped mussel (GLM), Perna canaliculus, is a nutraceutical that is rich in 
glycosaminoglycans (GAGs), omega-3 fatty acids, and eicosatetraenoic acid (ETA). 
GAGs play an important role in treatment of osteoarthritis as they exert anti-
inflammatory activities and lubricate joints. ETA also plays a role as it acts as a dual 
inhibitor of arachidonic acid oxygenation by COX and lipoxygenase pathways. Use of 
GLM has a similar mechanism of action as NSAIDs without adverse side effects. GLM is 
a gastroprotective agent and does not affect platelet aggregation. This suggests that ETA 
may be selective in only blocking COX-2 while sparing COX-1. There have been no 
reported adverse side effects from administration of GLM (Gupta et al, 2019a). 
          Iron transport tocopheryl polyethylene glycol succinate (ITPGS) exerts several 
biological and pharmacological actions (antioxidative, anti-inflammatory, and 
immunomodulatory) through multiple mechanisms. ITPGS in Flex Choice, by serving as 
bioenhancer, might have improved the absorption and bioavailability of ingredients that 
have anti-osteoarthritic properties (Srivastava et al., 2019).  
Theoretical Framework 
 
 At the base of this theoretical framework is knowledge that there is no known 
cure for osteoarthritis. Management practices are the only way to keep affected animals 
comfortable and these practices include medications, nutraceuticals, weight management, 
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and surgery. With this knowledge, several researchers have set out to try and find new 
medications, procedures, and nutraceuticals that will provide animals utmost comfort and 
relief from pain.  
 Nutraceuticals are becoming more and more popular for use in veterinary 
medicine to help alleviate signs and symptoms of common problems, including 
osteoarthritis. New nutraceuticals are being discovered and tested by researchers on a 
regular basis. Flex Choice is a new nutraceutical that was studied as a part of this thesis 
study in hopes of finding a new product to help with signs and symptoms associated with 
osteoarthritis.  
 By providing more than one option to manage osteoarthritis, owners will have a 
chance to choose which product or procedure that will fit best with their budget and 
lifestyle. Medications are an option and relieve symptoms while nutraceuticals have been 
shown to provide joints with ingredients needed to prevent further damage. Surgery is an 
option, although expensive, if medications or nutraceuticals are not effective or an 
underlying issue is causing osteoarthritis. 
Summary 
 
 This review of literature described many methods that provide pain management 
for dogs affected by osteoarthritis. There is no cure for this debilitating disease, but there 
are steps that can be taken to minimize pain. Owners can choose to put their dogs on 
medication to alleviate pain, try administering a nutraceutical to help with signs and 
symptoms, use weight management and physical therapy to help prevent further damage, 
or surgery. Out of these options, nutraceuticals are popular as there are new ones put on 
the market all the time. According to literature, there are already many nutraceuticals 
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available today, but researchers are trying and testing new compounds and combining 
compounds in hopes of finding one that is even better and has less long-term effects than 
the ones before. This will give owners options to try different formulas to see what works 
best for their dog. The purpose of this study was to test the efficacy and safety of a new 






The purpose of this study was to observe and analyze effects of Flex Choice 
(provided by Vets Plus, Inc. of Menomonie, WI) on moderately osteoarthritic dogs over a 
150-day period. The study was designed to examine whether or not Flex Choice would 
alleviate some of the pain associated with arthritis. This study was also conducted to 
determine if any adverse effects occur in liver, kidney, or heart function due to 
administration of Flex Choice. Data was collected through subjective observations, 
including limb manipulation, physical exertion and overall pain levels and vital signs and 
blood serum chemistries. Objectives of this study were as follows: 
1. Determine if Flex Choice decreases pain and inflammation caused by arthritis 
based on subjective data, such as overall pain, pain during limb manipulation, and 
pain after physical exertion. 
2. Determine if Flex Choice may increase flexibility and range of motion in affected 
joints. 
3. Determine safety of Flex Choice by observing overall health, such as heart rate, 
respiration rate, temperature, and liver, kidney, and heart function. 
4. Evaluate before and after radiographs to determine if affected joints exhibited 
improvements. 
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Population and Sample Selection 
 
 This study was composed of five moderately osteoarthritic dogs that were 
selected based on limitations stated in Chapter I, such as weight and level of arthritis. 
Sources used to obtain dogs included flyers posted around Murray, KY, Humane Society 
of Calloway County, posts published on social media websites such as Facebook, and 
flyers sent to faculty and students of Murray State University. Limitations on weight 
reduced possible candidates as most interest came from owners of 70+ pound dogs. 
Population owners consisted of students and faculty of Murray State University. Owners 
volunteered their dogs by signing a consent form consenting the use of their dog, 
administering Flex Choice as directed, and meeting with the researcher every 30 days. 
This form is located in Appendix B. This selection was purposive and dependent on 
owners’ willingness to provide dogs. All five canines were used for duration of the study. 
Context of the Study 
 
 Study location remained consistent throughout the entire 150 days. Owners 
brought their dogs to Carmen Pavilion at Murray State University each month. Carmen 
Pavilion provided a neutral location for evaluation and had all amenities necessary for 
proper evaluations. Carmen Pavilion Laboratories provided ample room to perform 
physical examinations and pain evaluations as well as centrifuge blood samples. Long 
hallways located inside provided ample room for physical exertion, and radiograph 
equipment was available in a nearby suite of rooms. Weight in pounds was obtained 
through use of an electronic scale located just outside the radiology suite. Research was 





 Time series design is best suited to represent data within this study. All 5 dogs 
were included in the treated group and baseline values collected on Day 0 were used as 
controls. Dogs received Flex Choice soft chews orally twice daily. Subjective and 
objective data were collected on each dog starting with baseline values on Day 0 and 
ending on Day 150 with sample collections every 30 days in between. Due to some 
scheduling conflicts, some collections were not obtained exactly 30 days apart. Table 1 
below illustrates this study’s design. 








































Data Collection Methods 
 
 All data were collected from each of five canines every 30 days for the entire 
study duration, a total of 150 days. Dogs in this study were assessed using six different 
methods of subjective and objective measurements: pain assessment, physical 
examination, blood chemistry, complete blood counts, erythrocyte sedimentation rate, 
and radiography. Owners also received a questionnaire to fill out monthly to assess their 
dogs pain levels at home. This form is located in Appendix C. Physical exams and pain 
assessments were conducted by the researcher on Day 0 and every 30 days during study 




There were three main scales used to observe pain in arthritic canines: 
1. Overall pain was observed on a scale of 1-10 with 1 equaling slight pain and 10 
equaling severe and constant pain. Evaluations for overall pain included gait 
quality, rising from a sitting or lying position, and lowering into a sitting or lying 
position. Owner evaluations were also taken into consideration. 
2. Pain during limb manipulation was observed on a scale of 0-4 with a 2-2.5 
indicating moderate arthritis. Pain was assessed based on vocalization, body 
posture, resistance, flexibility, and range of motion. 
3. Pain after physical exertion was observed on a scale of 0-4 with 2-2.5 equaling 
moderate arthritis. Pain was assessed based on vocalization, body posture, 
flexibility, resistance, and range of motion after 2 minutes of jogging. Canines 
were evaluated for evidence of lameness during and after exercise. 
Objective Data 
 Objective data were recorded during physical examination on Day 0 and every 30 
days until Day 150. Heart rate and respiration rate were observed using a stethoscope. 
Results were recorded in beats per minute. Body temperature was recorded using a digital 
rectal thermometer set to degrees Fahrenheit. Body weight was measured using an 
electronic scale and recorded in pounds. Radiographs were taken on Days 0 and 150 to 
determine if administration of Flex Choice may reverse some arthritic changes in joints. 
Blood Collection 
 Blood samples were collected from canine research subjects using jugular or 
cephalic veins with a 20-gauge needle and a 5cc syringe. Samples were then placed into a 
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3.5 ml serum separator tube and a 2 ml EDTA tube. Serum separator tubes were allowed 
to clot for 20 minutes and then were centrifuged for ten minutes. Serum was then 
removed from the clot and placed in a 2 ml red top tube using a pipette. Samples were 
then refrigerated until transport to Murray State University Breathitt Veterinary Center 
Diagnostic Laboratory. Ms. Jean Miller of the clinical pathology department at Breathitt 
analyzed serum for kidney, liver, heart and muscle function biomarkers using a Beckman 
AU 480 serum analyzer and whole blood was used for an erythrocyte sedimentation rate 
(ESR) and complete blood count (CBC) using a Sysmex XT-2000iV. ESR was used to 
test for inflammatory biomarkers. 
Data Analysis 
 
 All data were subjected to Microsoft Excel data analysis. Data were analyzed 
using simple paired T-tests. Values from the T-tests with P < 0.05 were considered 
statistically significant when compared to Day 0 values. Graphs were also created using 
Microsoft Excel.  
Reliability and Validity 
 
 As with any research study, precautions must be taken in order to ensure 
credibility and trustworthiness of collected data and methods of analysis. In this study, 
steps were taken to ensure validity. For collection of subjective and objective data, exams 
and assessments were performed consistently in manner and order each month. This 
improved consistency when data was recorded in numerical form. Radiographs were also 
performed using identical techniques to ensure comparisons were accurate when 






 All five canines that participated in this study were used in the treatment group 
due to low population size selected for this study. Each owner was given 150 days’ worth 
of Flex Choice soft chews. Owners were instructed to orally administer one soft chew in 
the morning and one soft chew in the evening for 150 days. The researcher evaluated 
canine subjects on Days 0, 30, 60, 90, 120, and 150 at Carmen Pavilion at Murray State 
University. Each canine was evaluated for overall pain by observing pain from rising 
from a sitting or lying position, lowering into a sitting or lying position, overall gait, and 
owner’s observation of overall pain. Each canine was also evaluated for pain during limb 
manipulation by observing vocalization, flexibility, resistance, and range of motion. Pain 
after physical exertion was also evaluated after two minutes of jogging. Radiographs 
were performed on days 0 and 150 and then compared to observe any internal changes in 
joints. Blood samples were collected on Day 0 and every 30 days for the duration of the 
study, and serum samples were analyzed for changes in liver, kidney, and heart and 
muscle function.  
 All data were recorded and statistically analyzed and mean ± standard error of 
means were calculated for each parameter on Day 0 and every 30 days thereafter. All 
values are shown in Tables 2 through 9. Some values could not be calculated, such as 
respiration rates due to panting. 
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Oral administration of Flex Choice soft chews led to a significant reduction in 
pain in at least one of the final months of treatment and evaluation. Overall pain was 
significantly reduced starting on Day 30 (P < 0.05) and pain during limb manipulation 
was significantly reduced on Days 30 and 120 (P < 0.05) and pain after physical exertion 
was significantly reduced on Days 120 and 150 (P < 0.05). Body weight, temperature, 
respiration, and all but one blood serum chemistry analysis showed no statistical 
significance. Creatine kinase showed a significant reduction on Days 30 and 150 (P < 
0.05) and heart rate showed a significant reduction starting on Day 60 (P < 0.05). 
Overall Pain 
 Overall pain was evaluated in five canines over a period of 150 days. Baseline 
values were collected on Day 0 and canines were reevaluated every 30 days for study 
duration. Levels of overall pain were observed based on a scale of 1 to 10 with 1 
indicating slight pain and 10 indicating severe and constant pain. Canines used in this 
study had a baseline value of overall pain ranging from 4 to 6. Determination of pain 
levels were observed based on quality of gait, ability to rise from a sitting or lying 
position, ability to lower into a sitting or lying position, range of motion, vocalization, 
and body posture. Input from owners on monthly questionnaires were also taken into 
account as owners saw their dog on a daily basis. 
 Table 2 shows results from Day 0 through Day 150. Baseline values on Day 0 
showed a mean value of 4.6 ± 0.40, indicating pain from moderate arthritis. Overall pain 
was significantly reduced (P < 0.05) starting on Day 30 to 3.6 ± 0.40 and continued to 
have a significant reduction (P < 0.05) for Days 60, 90, 120, and 150 (3.6 ± 0.60, 3.4 ± 
0.51, 3.2 ± 0.49, and 2.4 ± 0.40 respectively) from Day 0.   
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Table 2: Effects of Flex Choice on Overall Pain Level in Arthritic Canines 
 













4.6 ± 0.40 
 


























3.6 ± 0.40 * 
 



























3.6 ± 0.60 * 
 












2.4 ± 0.40 * 
 
*Statistically different from the value of Day 0 (P < 0.05) 
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Pain During Limb Manipulation 
 Pain during limb manipulation was evaluated in five canines over a period of 150 
days. Baseline values were collected on Day 0 and canines were reevaluated every 30 
days for study duration. Levels of pain were observed on a scale of 0 to 4 with 0 
indicating no pain and 4 indicating severe and constant pain. Moderate arthritic canines 
would exhibit a 2 to 2.5 on this scale. Each limb was assessed in standing recumbency 
while simultaneously observing vocalization, body posture, stiffness/resistance, integrity, 
and crepitus in the joints. 
 Table 3 shows results of pain during limb manipulation from Day 0 to Day 150. 
Baseline values on Day 0 show a mean value of 2.0 ± 0.00. Pain during limb 
manipulation showed a significant reduction (P < 0.05) in pain to 1.6 ± 0.10 on Day 30 
and again on Day 120 to 1.3 ± 0.12 compared to Day 0. 
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Table 3: Effects of Flex Choice on Pain from Limb Manipulation in Arthritic Canines 
 













2.0 ± 0.00 
 





















































1.5 ± 0.22 
 












1.4 ± 0.24 
 
*Statistically different from the value of Day 0 (P < 0.05)  
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Pain After Physical Exertion 
 Pain after physical exertion was observed in five canines starting on Day 0 until 
Day 150. Baseline values were collected on Day 0 and canines were reevaluated every 30 
days for the study duration. Pain was observed on a scale of 0 to 4 with 0 indicating no 
pain and 4 indicating severe and constant pain. Moderately arthritic canines will exhibit a 
2 to 2.5 on this scale. All five dogs were assessed for pain after limb manipulation based 
on vocalization, body posture, flexibility, resistance, and range of motion after 2 minutes 
of jogging. Canines were also observed for evidence of lameness and exercise 
intolerance.  
 Table 4 shows results of pain after physical exertion from Day 0 to Day 150. 
Baseline values on Day 0 exhibited a mean value of 2.0 ± 0.00. Evaluation of pain after 
physical exertion resulted in statistically significant reduction (P < 0.05) in pain to 1.2 ± 




Table 4: Effects of Flex Choice on Pain after Physical Exertion in Arthritic Canines 
 













2.0 ± 0.00 
 


























2.1 ± 0.10 
 



























1.8 ± 0.20 
 












1.2 ± 0.25 * 
 
*Statistically different from the value of Day 0 (P < 0.05) 
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Effects of Flex Choice on Body Weight, Heart Rate, Respiration Rate, Temperature, 
and Biological Parameters in Serum. 
 Body weight, heart rate, respiration rate, temperature and biological parameters in 
serum were evaluated in all five canines starting with baseline values on Day 0 and 
reevaluated every 30 days thereafter for study duration. 
 Table 5 presents results of body weight in pounds for all five canines participating 
in this study. Body weight was recorded using an electronic scale located near the 
radiology suite in Carmen Pavilion. There were some fluctuations in weight, including 
some that went outside limitations of this study. Body weights were recorded in lbs 
(mean ± SEM). Mean value for Day 0 was 52.4 ± 5.71 and Day 150 was 52.6 ± 6.57. No 
significant differences (P > 0.05) were observed in canine weight throughout study 
duration. 
 Table 6 presents results of heart rate in beats per minutes of five canine 
participants. Heart rate was observed using a stethoscope early in data collection process 
and values were recorded. The researcher attempted to keep canines as calm as possible 
to get an accurate recording. Some fluctuations were present due to canine excitement 
and nervousness. Mean value on Day 0 was 132.8 ± 11.55 with a significant difference (P 
< 0.05) observed starting on Day 60 (88.4 ± 7.33) and continued to have a significant 
reduction on Days 90, 120, and 150 (109.6 ± 15.88, 107.2 ± 10.84, and 112.8 ± 13.05 
respectively) compared to Day 0. This statistical significance could be due to many 
factors including level of excitement, level of pain, and nervousness. On Day 0, canines 
were very nervous and excited as they were in a new place with a new person performing 
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examinations. As each evaluation was complete, canines may have become more familiar 
with surroundings and comfortable with the researcher, therefore reducing heart rate.  
 Table 7 presents results of respiration rate in terms of breaths per minute of all 
five canines. Respiration rate was measured using a stethoscope early in data collection 
process and values were recorded. The researcher attempted to get an accurate 
measurement but panting interfered with valid measurement and values were unable to be 
obtained. Therefore, statistical analysis, as well as evaluation of the mean ± SEM, were 
not available. 
 Table 8 presents the results of temperature in terms of degrees Fahrenheit of all 
five canines. Temperature was measured by using a digital rectal thermometer and values 
were recorded. Mean value on Day 0 was 101.9 ± 0.27 and Day 150 was 101.4 ± 0.24. 
No significant differences (P > 0.05) were observed in all canines throughout study 
duration. 
 Table 9 presents data from serum chemistry parameters of all five canine 
participants. Blood chemistry parameters included BUN, creatinine, total bilirubin, direct 
bilirubin, ALT, AST, and creatine kinase. Blood samples were collected through 
venipuncture of either jugular or cephalic vein and serum was separated and transported 
to Breathitt Veterinary Center for analysis. There were some slight variations present 
possibly due to sample hemolysis and time between collection and analysis. Results of 
serum chemistries for BUN, creatinine, total bilirubin, direct bilirubin, ALT, and AST 
were not statistically significant (P > 0.05) from values of Day 0 throughout study 
duration. Creatine kinase was significantly reduced (P < 0.05) on Day 30 (106.0 ± 19.15) 
and Day 150 (112.8 ± 15.81) when compared to Day 0 (165.6 ± 18.17). This reduction 
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could be due to delayed sample analysis or individual canine variation as CK has a very 
short half-life in the blood. Even with a statistical reduction, the values for CK remained 
within reference interval. 
 Erythrocyte sedimentation (ESR) rates were performed, but values were not 
accurate due to delay in analysis from time of sample collection. Those results were 
discarded from this study. 
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Table 5: Effects of Flex Choice on Body Weight (lb.) of Arthritic Canines 
 









































52.8 ± 5.89 
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52.6 ± 6.57 





Table 6: Heart Rate/Min. of Arthritic Canines Treated with Flex Choice 
 






































































88.4 ± 7.33 * 
 












112.8 ±13.05 * 
 




Table 7: Respiration Rate/Min. of Arthritic Canines Treated with Flex Choice 
 

























































































Table 8: Temperature (ºF) of Arthritic Canines Treated with Flex Choice 
 
Day Dog Temp 
(ºF) 
Mean ± SEM  Day Dog Temp 
(ºF) 













101.9 ± 0.27 
 


























101.9 ± 0.62 
 



























101.5 ± 0.45 
 












101.4 ± 0.20 
 




Table 9: Biochemical Parameters of Canines Treated with Flex Choice 
 
 Day   
Parameter 0 30 60 90 120 150 
BUN 
mg/dl 
17.0 ± 3.59 17.4 ± 2.23 15.2 ± 1.98 13.2 ± 4.05 16.0 ± 3.05 18.2 ± 2.46 
CREAT 
mg/dl 
0.90 ± 0.09 
 
0.94 ± 0.06 0.92 ± 0.09 0.90 ± 0.10 0.90 ± 0.11 0.94 ± 0.10 
TBIL 
mg/dl 
0.18 ± 0.04 0.14 ± 0.02 0.16 ± 0.24 0.16 ± 0.02 0.14 ± 0.02 0.12 ± 0.02 
DBIL 
mg/dl 


































 Radiographs were taken on Day 0 and Day 150 on all five canines. Care was 
taken to attempt to keep technique and positioning the same on each day to improve 
comparison. There were no appreciable differences between radiographs from Day 0 to 
Day 150 observed on any canine. For proper comparison of joints on radiographs, 
positioning of each joint must be practically identical each time and this was not the case 
for this study. Canines were unable to be placed in exactly the same position for both 
radiograph sessions as different restrainers were used as well as expected movement from 
the canines. Technique used was as close to identical as possible, but some adjustments 
were made if the radiograph did not turn out appropriately on the first attempt. See 
Appendix E for radiographs. 
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Chapter V: Discussion and Conclusion
 
Discussion 
 Osteoarthritis is a chronic debilitating disease that does not discriminate. It effects 
both human and animals, with dogs suffering more often than other species due to 
excessive exercise, injury, obesity, genetic disposition, or poor nutrition. Approximately 
20 to 25% of the roughly 90 million dogs in the United States have been diagnosed with 
arthritis. This leads to researchers testing different remedies of easing pain, improving 
joint flexibility, and improving quality of life in those canines affected with this disease. 
Lifestyle changes such as weight loss management may help some canines, but others 
require medication to reduce the pain associated with arthritis. Non-steroidal anti-
inflammatories (NSAIDs) are the most commonly prescribed medications for 
management of arthritis. These medications, however, are not without risk. Canines may 
exhibit decreased appetite, vomiting, gastrointestinal irritation or ulceration, or 
hepatopathies with long term use (Merck, 2016). Due to these side effects, researchers 
and veterinarians are looking for new methods of pain management. 
 Nutraceuticals, such as Flex Choice, have become a popular choice among 
owners and veterinarians as they provide excellent pain management with little to no side 
effects and do not require a prescription. Canine participants in this study were given one 
Flex Choice soft chew twice daily for 150 days. Baseline values for overall pain, pain 
during limb manipulation, pain after physical exertion, vital signs, weight, and blood 
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chemistry parameters were obtained on Day 0 and reevaluated every 30 days for study 
duration. Evaluation of overall pain was based on a scale of 1 to 10 and canines were 
observed for quality of gait, vocalization, ability to sit, lay down, or stand, and body 
posture. Evaluation of pain during limb manipulation was based on a scale of 0 to 4 
observing vocalization, body posture, flexibility and range of motion, resistance, and 
crepitus of joints. Evaluation of pain after physical exertion was based on a scale of 0 to 
4, observing canines for vocalization, lameness, reluctance to move, and overall attitude 
after two minutes of jogging. Body weight, heart rate, respiration rate, temperature, and 
serum chemistry analysis were evaluated each time to ensure the safety of the canine 
throughout the entire duration of the study. Radiographs were taken on Day 0 and Day 
150 and then compared to observe if Flex Choice could reduce osteocyte formation in 
thoracic and pelvic limbs and hip joints. 
 Evaluations provided by canine owners were taken into consideration, and the 
researcher statistically analyzed data to determine if there was a significant reduction in 
pain. Administration of Flex Choice twice daily showed significant reduction in pain 
from arthritis over a 150-day period. Several owners commented about how they felt their 
dog was feeling better as they noticed a change in physical activity level during the study. 
One dog in particular was noted to be able to stand on slick floors again near Day 120 of 
the study. Difference in canines were visually noticeable upon study’s conclusion. 
Figures in the following section provide graphical evidence of significant differences in 
pain throughout the study. 
Figure 1 presents overall pain level of canines treated with Flex Choice. There 
was a significant reduction in pain by Day 30. Pain levels continued to reduce by Day 
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150. All canines benefited from treatment and pain levels were reduced from moderate 
pain to mild pain, with some showing more of a difference than others.  
Figure 2 presents pain during limb manipulation of canines treated with Flex 
Choice. There was a significant reduction in pain observed on Day 30 and Day 120, but 
then it increased slightly by Day 150. 
Figure 3 presents pain after physical exertion in treated canines. There was a 
significant reduction in pain by Day 120 and again on Day 150. Owners noticed a 
difference in their dog’s activity level around Day 90 and no comments about decreased 
activity were made at study’s conclusion on Day 150. 
Lateral radiographs of elbows, shoulders, and stifles as well as ventral dorsal 
radiographs of hips were obtained on Day 0 and Day 150 so comparison could be made. 
Radiograph quality was dependent on x-ray machine settings and movement of canines. 
Steps were taken to attempt consistent quality, but technique and views varied slightly 
from Day 0 to Day 150. There were no appreciable differences between Day 0 and Day 
150 radiographs. 
Physical examinations and blood collections were performed each month during 
study duration to ensure safety of Flex Choice. Serum samples were transported to 
Breathitt Veterinary Center for analysis. No significant differences overall were observed 
in canine serum chemistry values except for CK. CK was significantly reduced on Day 
30 and Day 150. This could be due to time from sample collection to analysis. One 
canine had elevated BUN values as a baseline at Day 0 of study, but level returned within 
reference intervals by Day 150. ALT level was elevated at Day 150 for this same canine. 
Body weight, heart rate, respiration rate, and temperature were also evaluated for 
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significant differences. Body weight did fluctuate slightly throughout study duration, but 
no significant differences were observed. Temperature remained steady throughout study 
duration. Heart rate seemed to lower as the study progressed, with a significant reduction 
starting on Day 60 and continued to be reduced for Days 90, 120, and 150. This could be 
due to canines becoming familiar with surroundings where research took place or reduced 
anxiety due to anticipation of treats. Respiration rate fluctuated throughout the study, but 
all canines except one were panting during each evaluation. There were no complaints 
from owners about loss of appetite, vomiting, diarrhea, or overall negative effects. 
Figure 1 
 
*Statistically different based on value of Day 0 (P < 0.05) 
 
* 
















 Results presented for overall pain, pain during limb manipulation, and pain after 
physical exertion concluded that administration of Flex Choice soft chews twice daily 
significantly reduced pain and inflammation associated with canine arthritis. Although 
there was no control group to compare results to, comparisons were made using baseline 
values from Day 0. Through physical examination, pain level analysis, and serum 
chemistry analysis, Flex Choice has been proven as an effective and safer alternative to 











Appendix B: Owner Consent Form 
 
 
Owner’s Names: ____________________________________________________ 
Address: __________________________________________________________ 
Phone: ____________________________ Alternate Phone: _________________ 
Canine’s Name: ____________________________________________________ 
Breed: _____________________________________Age: ___________________ 
 
As the owner or authorized agent of the above animal, I give consent for the use of this 
animal in the research project of Rachael Webber.  The study is outlined as follows: To 
observe the effects of this joint supplement on moderately arthritic canines that are not 
currently receiving treatment.  I understand that participation is voluntary and will 
continue for a period of 5 months (150 days).  During the 150 days, I am responsible for 
giving the canine oral soft chew daily throughout the entire time period.  Other 
responsibilities will include completion of monthly questionnaires and monthly meetings 
with Rachael Webber, who will perform physical observations and collect blood samples.  
These meetings will occur on Day 0, Day 30, Day 60, Day 90, Day 120, and Day 150 of 
the study.  I also consent to withdraw all other arthritis medications the canine may be 
receiving throughout the duration of the study.  Other medications, such as heartworm 
and other parasite control and prevention, can still be administered. 
 
Owner Signature: ___________________________________________________ 
Date: _____________________________________________________________ 
  





Appendix C: Owner Questionnaire 
 
Animal Name: ___________________________________ 
Owner Name: ____________________________________ 
 
1) On a scale of 1-10 (10 being most painful), rank your pets current pain: ____ 
 





4=severe and constant pain 
 
2) Does your dog have a difficult time raising his/her limbs? ______  
 
3) Does your dog experience stiffness in the limbs after extended periods of standing or 
sitting? ______ 
 
4) Does your dog express or whimpers in pain when limbs are manipulated? ______ 
 
5) Is your dog tender when touched in the hip/rear area? _____ 
 
6) Does your dog experience difficulty going up or downs stairs? _____ 
 
7) Is your dog more stiff/painful during times of cold weather? _____ 
 
8)  Does your dog experience lameness after physical exertion (i.e., walks, running, 
playing)? _____ 
 
9) Does your dog have difficulty jumping on to furniture, cars, or other objects? ____ 
 
Please Answer Yes or No for Questions 10-13: 
 
10)  Does your dog whimper, growl, snap, or any other negative outrages when touched? 
_____ 
 
12) Has your dog been diagnosed with being overweight by a veterinarian? _____ 
 
13) Has your dog been diagnosed by a licensed veterinarian with arthritis? ______ 
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Appendix D: Researchers Forms 
 
Patient Name: __________________ 
Owner Name: ___________________ 
Date of Observation: ______________ 
Weight: ________________ 
Heart Rate: _____________ 
Respiration Rate: ________ 
Temperature: ____________ 
 























Evaluation Date: ____________ 
 
Overall perceived pain level:         1     2     3     4     5     6     7     8     9     10 
1=No pain evident during exam 
5=Moderate pain evident  
10=Severe and constant pain evident 
 
Pain while rising from a sitting position   1   2    3     4     5     6     7     8     9     10 
 
Pain while rising from a lying position     1   2    3     4     5     6     7     8     9     10 
 
Pain while lowering body into sitting       1   2    3     4     5     6     7     8     9     10 
or lying positions 
 
 
Pain during limb manipulation 0     1     2     3     4 
0=No pain evident 
1=Mild pain evident 
2=Moderate pain evident 
3=Severe pain evident 
4=Severe and constant pain evident 
 
Apparent lameness after 3-minute physical exertion  0     1     2     3     4 
 




 Appendix E: Radiographs 
 
Radiographs of Bailey 
 
 
Day 0: Right Lateral view of Thoracic Limbs 
 
 
Day 0: Right Lateral view of Stifles 
Day 150: Right Lateral view of Thoracic Limbs 
Day 150: Right Lateral view of Stifles 
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Day 0: VD view of Hips 
 
Day 150: VD view of Hips 
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Radiographs of Brutus 
 
 
Day 0: Right Lateral view of Elbows 
 
Day 150: Right Lateral view of Elbows 
 
Day 0: Left Lateral view of Stifles 
 
Day 150: Left Lateral view of Stifles 
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Day 0: VD view of Hips 
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Radiographs of Lucchese 
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Radiographs of Reecey 
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